Zygomycosis: An emerging fungal infection

American Journal of Health-System Pharmacy

Volumn 62, Issue 24, 2005, Pages 2593-2596

  Brown, Jack ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Amphotericin B; Antifungals; Debridement; Deferoxamine; Diabetes mellitus; Diagnosis; Drug abuse; Epidemiology; Heavy metal antagonists; Immunosuppression; Pediatrics; Pocanazole; Toxicity; Transplantation; Zygomycosis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; DEFEROXAMINE; POSACONAZOLE; TRIAZOLE DERIVATIVE;

AUTOPSY; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; DEBRIDEMENT; DIABETES MELLITUS; DYSPNEA; FEVER; FUNGUS SPORE; FUNGUS TRANSMISSION; GASTROINTESTINAL SYMPTOM; HEMOPTYSIS; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; LUNG CAVITATION; LUNG DISEASE; MORBIDITY; MUCORALES; MUCORMYCOSIS; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; THROMBOSIS; TISSUE NECROSIS; UNITED STATES; ZYGOMYCETES;

EID: 32044438956     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050188     Document Type: Review

References (47)

1. Kume H, Yamazaki T, Abe M. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int. 2003; 53:744-50.
2. Konoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. J Infect Dis. 2005; 191:1350-60.
3. Ribes JA, Vanover-Sama CL, Baker DL Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13:236-301.
4. Kwon-Chung KJ, Bennett JE. Medical mycology. Philadelphia: Lea & Febiger; 1992:524-59.
5. Marchevsky AM, Bottone EJ, Geller SA et al. The changing spectrum of disease, etiology, and diagnosis of mucormycosis. Hum Pathol. 1980; 11:457-64.
6. Rippon JW. Zygomycosis. In: Rippon JW, ed. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia: Saunders; 1988.
7. Tedder M, Spratt JA, Anstadt MP et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994; 57:1044-50.
8. Sutherland JC, Jones TH. Gastric mucormycosis: report of case in a Swazi. S Afr Med J. 1960; 34:161-3.
9. Neame P, Rayner D. Mucormycosis: a report on twenty-two cases. Arch Pathol. 1960; 70:143-50.
10. Lawson HH, Schmaman A. Gastric phycomycosis. Br J Surg. 1974; 61:743-6.
11. Leeming LG, Moss HA, Elliott TS. Risk of tongue depressors to the immunocompromised. Lancet. 1996; 348:889. Letter.
12. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002; 16:895-914.
13. Roden MM, Buchanan W, Knudsen T et al. Epidemiology and outcome of zygomycosis: a review of 631 cases. Paper presented at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2004 Oct 30-Nov 2.
14. Kaufman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis. 2004; 39:588-90.
15. Kontoyiannis DP, Wessel VC, Bodey GP et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000; 30:851-6.
16. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34:909-17.
17. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005; 40:770-1.
18. Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005; 40:e35-7.
19. Kobayashi K, Kami M, Murashige N et al. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica. 2004; 89:e42.
20. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004; 39:584-7.
21. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004; 350:950-2.
22. Imhof A, Balajee SA, Fredricks DN. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004; 39:743-6.
23. Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis. 2004; 36:312-4.
24. Ritz N, Ammann RA, Aebischer CC et al. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr. 2005; 164:231-5.
25. Lionakis MS, Kontoyiannis DP. Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br J Haematol. 2005; 129:2.
26. Levitz SM, Selsted ME, Ganz T et al. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986; 154:483-9.
27. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun. 1982; 38:487-95.
28. Ibrahim AS, Edwards JE, Filler SG. Zygomycosis. In: Dismukes WE, Pappas PG, Sobel JD, eds. Clinical mycology. New York: Oxford Univ. Press; 2003:241-51.
29. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases: GIMEMA Infection Program. Br J Haematol. 1997; 99:331-6.
30. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999; 159:1301-9.
31. Larkin JA, Montero JA. Fungal infection efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med. 2003; 20:201-6.
32. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26:1383-96.
33. Costa AR, Porto E, Tayah M et al. Subcutaneous mucormycosis caused by Mucor heimalis. Mycoses. 1990; 33:241-6.
34. Funada H, Miyake Y, Kanamori K et al. Fluconazole therapy for pulmonary mucormycosis complicating acute leukemia. Jpn J Med. 1989; 28:228-31.
35. Barnert J, Behr W, Reich H. An amphotericin B resistant case of rhinocerebral zygomycosis. Infection. 1985; 13:134-6.
36. Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses. 2004; 47:159-62.
37. Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003; 41:3623-6.
38. Eisen E, Meletiadis J, Mouton JW et al. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003; 51:45-52.
39. Sun QN, Fothergill AW, McCarthy DI et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother. 2002; 46:1581-2.
40. Greenberg RN, Herbrecht R, Langston A et al. Posaconazole treatment for refractory invasive zygomycosis. Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003 Sep 14-17.
41. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycoses in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony stimulating factor. Clin Infect Dis. 1997; 25:192-6.
42. Leleu X, Sendid B, Fruit J et al. Combination antifungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999; 24:417-20.
43. Sahin B, Paydas S, Cosar B et al. Role of granulocyte colony stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis. 1996; 15:866-9.
44. Antman K, Griffin J, Elias A. Effect of recombinant human granulocyte macrophage colony stimulating factor on chemotherapy induced myelosuppression. N Engl J Med. 1988; 319:593-8.
45. Body GP, Anaissie E, Gutterman J et al. Role of granulocyte macrophage colony stimulating factor as adjuvant therapy in fungal infections in patients with cancer. Clin Infect Dis. 1993; 17:705-7.
46. Wright DG, Robichaud KJ, Pizzo PA et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981; 304:1185-9.
47. Heinz T, Perfect J, Schell W et al. Soft-tissue fungal infections: surgical management of 12 immunocompromised patients. Plast Reconstr Surg. 1996; 97:1391-9.